Published Evidence Supporting Ref-1 Inhibition

Peer-reviewed publications across mechanism, IBD and gut biology, systemic inflammation, and clinical trials, establishing the scientific rationale for APX3330 as a novel upstream therapy for Inflammatory Bowel Disease.

APX3330 Mechanism

2025 Rai et al., Protein Science 2025. PMID / DOI: TBD

IBD & Gut

2023 Ephraim et al. 2023. Journal & PMID: TBD

2023 Stavely et al., Biomolecules 2023. PMID: 38002251

2022 Sahakian et al., Adv Exp Med Biol 2022. PMID / DOI: TBD

2020 Sahakian et al., Inflammatory Bowel Diseases 2020. PMID: 32618996

Systemic Inflammation

2026NEW Kumar et al., Blood 2026. PMID / DOI: TBD

2026NEW Kumar et al., Communications Biology 2026. PMID / DOI: TBD

Clinical Trials

2026NEW Kelley et al., The Oncologist 2026. PMID / DOI: TBD

Review

Additional review publications forthcoming.

Interested in learning more?

Contact our team for investor, partnership, and clinical inquiries, or explore our published science.